Immunoinformatics analysis of Brucella melitensis to approach a suitable vaccine against brucellosis.
Brucellosis
Epitope prediction
Immunoinformatics
Multi-epitope vaccine
Journal
Journal, genetic engineering & biotechnology
ISSN: 2090-5920
Titre abrégé: J Genet Eng Biotechnol
Pays: Netherlands
ID NLM: 101317150
Informations de publication
Date de publication:
29 Nov 2023
29 Nov 2023
Historique:
received:
28
02
2023
accepted:
14
11
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Brucellosis caused by B. melitensis is one of the most important common diseases between humans and livestock. Currently, live attenuated vaccines are used for this disease, which causes many problems, and unfortunately, there is no effective vaccine for human brucellosis. The aim of our research was to design a recombinant vaccine containing potential immunogenic epitopes against B. melitensis. In this study, using immunoinformatics approaches, 3 antigens Omp31, Omp25, and Omp28 were identified and the amino acid sequence of the selected antigens was determined in NCBI. Signal peptides were predicted by SignaIP-5.0 server. To predict B-cell epitopes from ABCpred and Bcepred servers, to predict MHC-I epitopes from RANKPEP and SYFPEITHI servers, to predict MHC-II epitopes from RANKPEP and MHCPred servers, and to predict CTL epitopes were used from the CTLPred server. Potentially immunogenic final epitopes were joined by flexible linkers. Finally, allergenicity (AllerTOP 2.0 server), antigenicity (Vaxijen server), physicochemical properties (ProtParam server), solubility (Protein-sol server), secondary (PSIPRED and GRO4 servers) and tertiary structure (I-TASSER server), refinement (GalaxyWEB server), validation (ProSA-web, Molprobity, and ERRAT servers), and optimization of the codon sequence (JCat server) of the structure of the multi-epitope vaccine were analyzed. The analysis of immunoinformatics tools showed that the designed vaccine has high quality, acceptable physicochemical properties, and can induce humoral and cellular immune responses against B. melitensis bacteria. In addition, the high expression level of recombinant antigens in the E. coli host was observed through in silico simulation. According to the results in silico, the designed vaccine can be a suitable candidate to fight brucellosis and in vitro and in vivo studies are needed to evaluate the research of this study.
Sections du résumé
BACKGROUND
BACKGROUND
Brucellosis caused by B. melitensis is one of the most important common diseases between humans and livestock. Currently, live attenuated vaccines are used for this disease, which causes many problems, and unfortunately, there is no effective vaccine for human brucellosis. The aim of our research was to design a recombinant vaccine containing potential immunogenic epitopes against B. melitensis.
METHODS
METHODS
In this study, using immunoinformatics approaches, 3 antigens Omp31, Omp25, and Omp28 were identified and the amino acid sequence of the selected antigens was determined in NCBI. Signal peptides were predicted by SignaIP-5.0 server. To predict B-cell epitopes from ABCpred and Bcepred servers, to predict MHC-I epitopes from RANKPEP and SYFPEITHI servers, to predict MHC-II epitopes from RANKPEP and MHCPred servers, and to predict CTL epitopes were used from the CTLPred server. Potentially immunogenic final epitopes were joined by flexible linkers. Finally, allergenicity (AllerTOP 2.0 server), antigenicity (Vaxijen server), physicochemical properties (ProtParam server), solubility (Protein-sol server), secondary (PSIPRED and GRO4 servers) and tertiary structure (I-TASSER server), refinement (GalaxyWEB server), validation (ProSA-web, Molprobity, and ERRAT servers), and optimization of the codon sequence (JCat server) of the structure of the multi-epitope vaccine were analyzed.
RESULTS
RESULTS
The analysis of immunoinformatics tools showed that the designed vaccine has high quality, acceptable physicochemical properties, and can induce humoral and cellular immune responses against B. melitensis bacteria. In addition, the high expression level of recombinant antigens in the E. coli host was observed through in silico simulation.
CONCLUSION
CONCLUSIONS
According to the results in silico, the designed vaccine can be a suitable candidate to fight brucellosis and in vitro and in vivo studies are needed to evaluate the research of this study.
Identifiants
pubmed: 38019359
doi: 10.1186/s43141-023-00614-6
pii: 10.1186/s43141-023-00614-6
pmc: PMC10686926
doi:
Types de publication
Journal Article
Langues
eng
Pagination
152Informations de copyright
© 2023. The Author(s).
Références
PLoS Negl Trop Dis. 2012;6(10):e1865
pubmed: 23145195
PLoS One. 2017 Oct 12;12(10):e0186484
pubmed: 29023541
Int J Infect Dis. 2008 Nov;12(6):573-7
pubmed: 18539496
Proteins. 2003 Feb 15;50(3):437-50
pubmed: 12557186
J Biomed Biotechnol. 2010;2010:218590
pubmed: 21772787
BMC Bioinformatics. 2007 Jan 05;8:4
pubmed: 17207271
Infect Immun. 1998 Nov;66(11):5561-4
pubmed: 9784574
Rev Sci Tech. 2013 Apr;32(1):43-51, 53-60
pubmed: 23837364
Hum Vaccin. 2005 May-Jun;1(3):95-101
pubmed: 17012851
J Biomol Struct Dyn. 2021 May;39(8):2857-2872
pubmed: 32295479
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W384-8
pubmed: 23737448
Ann Agric Environ Med. 2013;20(2):233-8
pubmed: 23772567
Vaccines (Basel). 2023 Jan 19;11(2):
pubmed: 36851099
Vaccines (Basel). 2023 Mar 14;11(3):
pubmed: 36992237
BMC Vet Res. 2022 Feb 15;18(1):71
pubmed: 35168621
J Mol Biol. 1999 Sep 17;292(2):195-202
pubmed: 10493868
Iran Biomed J. ;21(6):349-59
pubmed: 28766326
Chem Sci. 2016 Feb 1;7(2):842-854
pubmed: 28791117
Immunogenetics. 2004 Sep;56(6):405-19
pubmed: 15349703
Proteins. 2006 Oct 1;65(1):40-8
pubmed: 16894596
Nucleic Acids Res. 2001 Jan 1;29(1):308-11
pubmed: 11125122
Croat Med J. 2010 Aug;51(4):296-305
pubmed: 20718082
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W375-83
pubmed: 17452350
Nat Methods. 2015 Jan;12(1):7-8
pubmed: 25549265
BMC Bioinformatics. 2008 Jan 23;9:40
pubmed: 18215316
Adv Drug Deliv Rev. 2013 Oct;65(10):1357-69
pubmed: 23026637
Vet Res Commun. 2010 Feb;34(2):119-32
pubmed: 20013309
Immunome Res. 2010 Nov 03;6 Suppl 2:S2
pubmed: 21067544
Innate Immun. 2018 Aug;24(6):382-389
pubmed: 30092685
BMC Vet Res. 2015 Nov 03;11:275
pubmed: 26530141
Nat Biotechnol. 2019 Apr;37(4):420-423
pubmed: 30778233
Curr Pharm Biotechnol. 2013;14(10):887-96
pubmed: 24372253
Int Immunopharmacol. 2019 Oct;75:105829
pubmed: 31437796
Sci Rep. 2019 Mar 5;9(1):3512
pubmed: 30837598
Asian Pac J Cancer Prev. 2013;14(10):5973-81
pubmed: 24289611
Immunogenetics. 1999 Nov;50(3-4):213-9
pubmed: 10602881
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W407-10
pubmed: 17517781
Vaccine. 2004 Aug 13;22(23-24):3195-204
pubmed: 15297074
J Commun Dis. 2002 Dec;34(4):287-301
pubmed: 14710861
J Equine Vet Sci. 2023 Apr;123:104227
pubmed: 36649828
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W526-31
pubmed: 15980527
Bioinformatics. 2005 Jun 1;21(11):2787-8
pubmed: 15797907
Biotechniques. 2000 Jun;28(6):1102, 1104
pubmed: 10868275
J Mol Model. 2014 Jun;20(6):2278
pubmed: 24878803
Infect Drug Resist. 2022 Sep 07;15:5301-5308
pubmed: 36101776
Nucleic Acids Res. 2003 Jul 1;31(13):3621-4
pubmed: 12824380
Nat Biotechnol. 2006 Nov;24(11):1377-83
pubmed: 17093488
Ann Rech Vet. 1983;14(3):311-8
pubmed: 6419668
Protein Sci. 1993 Sep;2(9):1511-9
pubmed: 8401235
Nanomedicine (Lond). 2014 Dec;9(17):2657-69
pubmed: 25529569
Clin Diagn Lab Immunol. 2004 Jan;11(1):111-4
pubmed: 14715555
Neurology. 1985 Nov;35(11):1576-81
pubmed: 3877254
Vaccine. 2009 Nov 5;27 Suppl 4:D40-3
pubmed: 19837284
Iran Biomed J. 2022 Jan 29;26(2):160-74
pubmed: 35090304
Microb Pathog. 2018 Feb;115:50-56
pubmed: 29253594
J Biomol Struct Dyn. 2021 Nov;39(18):6882-6902
pubmed: 32772811
Bioinformatics. 2017 Oct 01;33(19):3098-3100
pubmed: 28575391